Testing AZD5363 as a Potential Targeted Treatment in Cancers With AKT Genetic Changes (MATCH-Subprotocol Y)

Summary

This phase II MATCH treatment trial identifies the effects of AZD5363 in patients whose cancer has a genetic change called AKT mutation. AZD5363 may block AKT, which is a protein needed for cancer cell growth. Researchers hope to learn if AZD5363 will shrink this type of cancer or stop its growth.

Timeline

Start

2016-05-31

Primary completion

2019-11-08

Completion

2027-03-31

Publications

• McCourt CK, Gross J, Kalinsky K, Guan P, McShane LM, Wang V, O'Dwyer PJ, Lahey MT, Maican C, Bu X, Patton D, Harris LN. Comprehensive Molecular and Genomic Analysis of NCI-MATCH Subprotocol Y: Capivasertib in Patients With an AKT1 E17K-Mutated Tumor. JCO Precis Oncol. 2025 Mar;9:e2400614. doi: 10.1200/PO-24-00614. Epub 2025 Mar 28.

Drugs

Indications